Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 69

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 69
---
MENTS IN EQUITY SECURITIES         As of   December 31,  December 31,   2024  2023 As of beginning of the year $1,699,831  $1,150,898 Addition during the year  492,732   320,733 Disposal during the year  (1,030,368)  (26,146)Fair value gains  69,476   313,859 Impairment during the year     -   (6,194)Foreign exchange translation   33,495   (53,319)As of end of the year $1,265,166  $1,699,831  For the year ended December 31, 2024 and 2023, the net fair value gains on the investments in equity securities were $69,476 and $313,859 recorded in other income of the Consolidated Statements of Operations and Comprehensive Income/(Loss).   The investments in equity securities consist of the following shares:        As of   December 31,  December 31,   2024  2023 Investment in equity securities with readily determined fair value:      Malaysia  863,810   1,138,863 Singapore  177,808   79,577 Hong Kong  -   481,391   $1,041,618  $1,699,831 Investment in equity securities without readily determined fair value:        Malaysia  223,548   -   $1,265,166  $1,699,831  The Company’s investment in equity securities is measured at fair value on a recurring basis. These equity securities are classified as Level 1 in the fair value hierarchy, as the fair value is determined using quoted market prices in active markets for identical assets. Specifically, the stock prices of these securities are readily available on the stock exchange, providing a reliable and observable input to the fair value measurement. As these securities are actively traded, the quoted prices in the market are considered to be the most reliable indicator of fair value. No significant adjustments are made to these prices, as they reflect current market conditions at the measurement date.

 F-22Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONSOLIDATED